These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29581078)

  • 1. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
    White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
    Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
    Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
    Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
    Del Prato S; Camisasca R; Wilson C; Fleck P
    Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
    Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
    Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
    White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
    N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial.
    Park JY; Lee J; Choi YH; Min KW; Han KA; Ahn KJ; Lim S; Kim YH; Ahn CW; Choi KM; Yoon KH
    Diabetes Metab J; 2024 Sep; 48(5):915-928. PubMed ID: 38650099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
    Kim JM; Kim SS; Kim JH; Kim MK; Kim TN; Lee SH; Lee CW; Park JY; Kim ES; Lee KJ; Choi YS; Kim DK; Kim IJ
    Diabetes Metab J; 2020 Feb; 44(1):67-77. PubMed ID: 31339011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
    Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
    J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
    Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E; Ellis GC; Wilson CA; Fleck PR
    Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
    Pratley RE; Fleck P; Wilson C
    Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
    Rosenstock J; Wilson C; Fleck P
    Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.